Program
VG712
A development code.
Its studies are mostly in Mycosis Fungoides, led by Virogen Biotechnology.
Furthest: phase 2, since Mar 20, 20261 company-led study, 1 open or runningNext primary completion: Dec 30, 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Virogen Biotechnology | 11 open or running | phase 2since Mar 20, 2026 | Mar 20, 2026 | Dec 30, 2030phase 2 · NCT07529405 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 20, 2026First study: phase 2 study in Mycosis FungoidesFirst studyNCT07529405 · 386 planned · United States
Ahead
- Dec 30, 2030Primary completion: phase 2 study in Mycosis FungoidesNCT07529405
TargetBeta
CD3E →read by rule
“VG712 is a recombinant anti-CD3 immunotoxin designed to selectively deplete CD3-positive T cells.”study text, by rule · the study
Other programs on CD3E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| etentamig | AbbVie | phase 3 | 11 |
| obrixtamig | Boehringer Ingelheim | phase 3 | 11 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| cevostamab | Hoffmann-La Roche | phase 3 | 8 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| pasritamig | Johnson & Johnson | phase 3 | 5 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| gocatamig | Merck | phase 3 | 4 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07529405Mycosis Fungoides · United States | 2 | Not yet recruiting | Dec 30, 2030 | 386 |
How it is read
Names in the registry
- “VG712”, 1 entry
Codes read as this program: VG712.
Conditions, from the studies’ own filings
- Mycosis Fungoides, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.